Vaccines (Dec 2020)

Cationic Polymers for the Delivery of the Ebola DNA Vaccine Encoding Artificial T-Cell Immunogen

  • Larisa I. Karpenko,
  • Evgeny K. Apartsin,
  • Sergei G. Dudko,
  • Ekaterina V. Starostina,
  • Olga N. Kaplina,
  • Denis V. Antonets,
  • Ekaterina A. Volosnikova,
  • Boris N. Zaitsev,
  • Anastasiya Yu. Bakulina,
  • Aliya G. Venyaminova,
  • Alexander A. Ilyichev,
  • Sergei I. Bazhan

DOI
https://doi.org/10.3390/vaccines8040718
Journal volume & issue
Vol. 8, no. 4
p. 718

Abstract

Read online

Background: According to current data, an effective Ebola virus vaccine should induce both humoral and T-cell immunity. In this work, we focused our efforts on methods for delivering artificial T-cell immunogen in the form of a DNA vaccine, using generation 4 polyamidoamine dendrimers (PAMAM G4) and a polyglucin:spermidine conjugate (PG). Methods: Optimal conditions were selected for obtaining complexes of previously developed DNA vaccines with cationic polymers. The sizes, mobility and surface charge of the complexes with PG and PAMAM 4G have been determined. The immunogenicity of the obtained vaccine constructs was investigated in BALB/c mice. Results: It was shown that packaging of DNA vaccine constructs both in the PG envelope and the PAMAM 4G envelope results in an increase in their immunogenicity as compared with the group of mice immunized with the of vector plasmid pcDNA3.1 (a negative control). The highest T-cell responses were shown in mice immunized with complexes of DNA vaccines with PG and these responses significantly exceeded those in the groups of animals immunized with both the combination of naked DNAs and the combination DNAs coated with PAMAM 4G. In the group of animals immunized with complexes of the DNA vaccines with PAMAM 4G, no statistical differences were found in the ability to induce T-cell responses, as compared with the group of mice immunized with the combination of naked DNAs. Conclusions: The PG conjugate can be considered as a promising and safe means to deliver DNA-based vaccines. The use of PAMAM requires further optimization.

Keywords